BRIEF published on 12/22/2025 at 07:05, 7 months 11 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
PRESS RELEASE published on 12/22/2025 at 07:00, 7 months 11 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 8 months 19 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 9 months 3 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 10 months 2 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 10 months 2 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 10 months 2 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 11 months 4 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 11 months 4 days ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 1 year ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
Published on 08/01/2026 at 01:20, 1 day 18 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 1 day 18 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 1 day 18 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 1 day 20 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/02/2026 at 08:15, 11 hours 4 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 1 day 2 hours ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 19:55, 1 day 23 hours ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA Reaches Agreement with Financing Partners on Extension of Standstill Agreement and Continuation of Restructuring Process
Published on 07/31/2026 at 19:05, 2 days ago Eurobattery Minerals presents the Q2 report for 2026 as the Company accelerates the development of the San Juan tungsten project
Published on 07/31/2026 at 21:00, 1 day 22 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:13, 2 days ago Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
